[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336386-105":59,"doc-detail-336386-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trpv6-channel-targeting-using-monoclonal-antibody-induces-prostate-cancer-cell-apoptosis-and-tumor-regression-research-paper","Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression - Research Paper","","TRPV6 calcium channel is identified as a prospective target in prostate cancer because it is absent in healthy prostate yet increases during cancer progression. Mouse monoclonal antibody mAb82 was generated against an extracellular pore-region epitope and inhibited TRPV6 currents dose-dependently, reducing store-operated calcium entry. mAb82 induced apoptosis in prostate cancer cells via a calpain activation pathway downstream of Bax, leading to caspase 3/7 activation, and significantly suppressed tumor growth in vivo with minimal toxicity. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trpv6-channel-targeting-using-monoclonal-antibody-induces-prostate-cancer-cell-apoptosis-and-tumor-regression-research-paper/336386/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trpv6-channel-targeting-using-monoclonal-antibody-induces-prostate-cancer-cell-apoptosis-and-tumor-regression-research-paper/336386.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is TRPV6 considered a therapeutic target in prostate cancer?","Question",{"text":112,"@type":113},"TRPV6 is absent in healthy prostate, but its expression appears de novo in prostate cancer and correlates with malignancy progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does monoclonal antibody mAb82 affect TRPV6 activity and calcium entry?",{"text":117,"@type":113},"mAb82 inhibited TRPV6 currents in a dose-dependent manner and reduced store-operated calcium entry.",{"name":119,"@type":110,"acceptedAnswer":120},"What anti-tumor effects were observed with mAb82 in vivo?",{"text":121,"@type":113},"In mouse tumor models, mAb82 treatment led to a significant reduction in tumor growth and improved survival, with organ distribution dependent on TRPV6 expression and virtually no toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336386,1790146018,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nTrpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression  \nAurélien Haustrate1,2, Clément Cordier 1, George Shapovalov1, Adriana Mihalache3, Emilie Desruelles 1, Benjamin Soret 1,  \nNadège Charlène Essonghé 1, Corentin Spriet4, Maya Yassine1, Alexandre Sabine Szunerits5, Gautier Robin6, Pierre Gosset3, Natalia Prevarskaya 1  \n© The Author(s) 2024  \nBarras5, Johanna and V’yacheslav  \nMarines6, Lindsay B. Alcaraz6, Lehen’kyi 1,2 ✉  \n\n| | TRPV6 calcium channel is a prospective target in prostate cancer (PCa) since it is not expressed in healthy prostate while its expression increases during cancer progression. Despite the role of TRPV6 in PCa cell survival and apoptotic resistance has been already established, no reliable tool to target TRPV6 channel in vivo and thus to reduce tumor burden is known to date. Here wereport the generation of mouse monoclonal antibody mAb82 raised against extracellular epitope of the pore region of the channel. mAb82 inhibited TRPV6 currents by 90% at 24 µg/ml in a dose-dependent manner while decreasing store-operated calcium entry to 56% at only 2.4 µg/ml. mAb82 decreased PCa survival rate in vitro by 71% at 12 µg/ml via inducing cell death through the apoptosis cascade via activation of the protease calpain, following bax activation, mitochondria enlargement, and loss of cristae, Cyt C release, pro-caspase 9 cleavage with the subsequent activation of caspases 3/7 . In vivo, mice bearing either PC3Mtrpv6+/+ or PC3Mtrpv6-/-+pTRPV6 tumors were successfully treated with mAb82 at the dose as low as 100 µg/kg resulting in a signiﬁcant reduction tumor growth by 31% and 90%, respectively. The survival rate was markedly improved by 3.5 times in mice treated with mAb82 in PC3Mtrpv6+/+ tumor group and completely restored in PC3Mtrpv6-/- +pTRPV6 tumor group. mAb82 showed a TRPV6-expression dependent organ distribution and virtually no toxicity in the same way as mAbAU1, a control antibody of the same Ig2aisotype. Overall, our data demonstrate for the ﬁrst time the use of an anti-TRPV6 monoclonal antibody in vitro and in vivo in the |  |  |  |  |  | |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n| | treatment of the TRPV6-expressing PCa tumors. |  |  |  |  |  | |\n|  | Cell Death and Disease (2024)15:419; [https://doi.org/10.1038/s41419-024-06809-0](https://doi.org/10.1038/s41419-024-06809-0) |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n\nINTRODUCTION  \nIon channels dysregulations are now well established entities of cancer hallmarks [1], being involved in virtually all malignant processes such as aberrant proliferation, apoptosis resistance, enhanced migration, invasion, tumor environment, angiogenesis, etc. [1–5] . Being expressed mostly on the plasma membrane, ion channels represent prospective targets in human pathophysiology since any ion channel-targeting drug would not need to cross the plasma membrane. On the other side, being essential to cell physiology, most ion channels have a wide, if not ubiquitous, distribution pattern which narrows their ﬁeld of application. In addition, the common origin of different groups of ion channels explains their molecular similarity especially at the level of highly conservative extracellular domains and makes them difﬁcult to target and to differentiate between them.  \nOne of these channels, TRPV6, has its role already well established in human cancerogenesis and was shown to be involved in many cancers of organs such as prostate, breast, colon, thyroid, ovary, and many others [6–9], being mostly described as a  \nproto","cbCainJrZr2w82e0","https://ap.wps.com/l/cbCainJrZr2w82e0","pdf",5811452,13,"English","# Introduction\n## TRPV6 as a cancer-associated ion channel\n## Rationale for targeting TRPV6 in prostate cancer\n## Prior attempts at TRPV6 inhibition","[{\"question\":\"Why is TRPV6 considered a therapeutic target in prostate cancer?\",\"answer\":\"TRPV6 is absent in healthy prostate, but its expression appears de novo in prostate cancer and correlates with malignancy progression.\"},{\"question\":\"How does monoclonal antibody mAb82 affect TRPV6 activity and calcium entry?\",\"answer\":\"mAb82 inhibited TRPV6 currents in a dose-dependent manner and reduced store-operated calcium entry.\"},{\"question\":\"What anti-tumor effects were observed with mAb82 in vivo?\",\"answer\":\"In mouse tumor models, mAb82 treatment led to a significant reduction in tumor growth and improved survival, with organ distribution dependent on TRPV6 expression and virtually no toxicity.\"}]","Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression - Research Paper | PDF",1790014810,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1112aab81a87647b5ca03355dfc097bb.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9fd472fc115af5ab574ea0f2cb00ed8.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/537edc00ad93185753cebc1559408e8a.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51bae66052a3900313c578968d8adf4d.webp",980,1301]